The DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.
Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy
Open accessAbstract
Conventional cytotoxic cancer chemotherapy is often immunosuppressive and associated with drug resistance and tumor regrowth after a short period of tumor shrinkage or growth stasis. However, certain cytotoxic cancer chemotherapeutic drugs, including doxorubicin, mitoxantrone, and cyclophosphamide, can kill tumor cells by an immunogenic cell death pathway, which activates robust innate and adaptive anti-tumor immune responses and has the potential to greatly increase the efficacy of chemotherapy. Here, we review studies on chemotherapeutic drug-induced immunogenic cell death, focusing on how the choice of a conventional cytotoxic agent and its dose and schedule impact anti-tumor immune responses. We propose a strategy for effective immunogenic chemotherapy that employs a modified metronomic schedule for drug delivery, which we term medium-dose intermittent chemotherapy (MEDIC). Striking responses have been seen in preclinical cancer models using MEDIC, where an immunogenic cancer chemotherapeutic agent is administered intermittently and at an intermediate dose, designed to impart strong and repeated cytotoxic damage to tumors, and on a schedule compatible with activation of a sustained anti-tumor immune response, thereby maximizing anti-cancer activity. We also discuss strategies for combination chemo-immunotherapy, and we outline approaches to identify new immunogenic chemotherapeutic agents for drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Dose translation from animal to human studies revisited.
Reagan‐Shaw, S., Nihal, M., & Ahmad, N. (2008) · The FASEB Journal · doi:10.1096/fj.07-9574lsf · Cited by 6,524
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632 · cited 1×
“Cancer is a disease of malignant cells that interact with and co-opt their environment in complex ways, stimulating tumor growth, angiogenesis, invasion and metastasis and fostering an immune suppressive environment that counters the tumoricidal effects of many cytotoxic anti-cancer agents [1].”
BackgroundCalreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 3×
“This release enables HMGB1 to interact with TLR4 expressed on DCs, thereby stimulating antigen presentation by DCs as well as DC production of IL1β, which activates CD8+ T cells [16,17].”
BackgroundThe NCI60 human tumour cell line anticancer drug screen
Shoemaker, R. H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1951 · Cited by 2,620
Comprehensive analyses of tumor immunity: implications for cancer immunotherapy
Li, B., Severson, E., Pignon, J.-C., Zhao, H., Li, T., Novak, J., Jiang, P., Shen, H., Aster, J. C., Rodig, S., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-1028-7 · Cited by 2,451
Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing
Zheng, C., Zheng, L., Yoo, J.-K., Guo, H., Zhang, Y., Guo, X., Kang, B., Hu, R., Huang, J. Y., Zhang, Q., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.035 · Cited by 2,152
Cancer immunotherapy via dendritic cells
Palucka, K., & Banchereau, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3258 · Cited by 2,049
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Coutinho, A. E., & Chapman, K. E. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.04.005 · Cited by 1,815
Immunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712
Adoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688
Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance
Elliott, M. R., Chekeni, F. B., Trampont, P. C., Lazarowski, E. R., Kadl, A., Walk, S. F., Park, D., Woodson, R. I., Ostankovich, M., Sharma, P., et al. (2009) · Nature · doi:10.1038/nature08296 · Cited by 1,654
Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,543
The anti-angiogenic basis of metronomic chemotherapy
Kerbel, R. S., & Kamen, B. A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1369 · Cited by 1,397
Cancer immunotherapy: harnessing the immune system to battle cancer
Yang, Y. (2015) · Journal of Clinical Investigation · doi:10.1172/jci83871 · Cited by 1,359
Cancer despite immunosurveillance: immunoselection and immunosubversion
Zitvogel, L., Tesniere, A., & Kroemer, G. (2006) · Nature reviews. Immunology · doi:10.1038/nri1936 · Cited by 1,324 · cited 2×
“Tumors unresponsive to the immunogenic actions of cyclophosphamide may be deficient in factors essential for ICD, such as stress ligands like MHC class I [23], or may express factors that confer resistance to ICD, such as PD-L1 [48].”
BackgroundThe DNA damage pathway regulates innate immune system ligands of the NKG2D receptor
Gasser, S., Orsulic, S., Brown, E. J., & Raulet, D. H. (2005) · Nature · doi:10.1038/nature03884 · Cited by 1,308
Ghiringhelli, F., Menard, C., Puig, P. E., Ladoire, S., Roux, S., Martin, F., Solary, E., Le Cesne, A., Zitvogel, L., & Chauffert, B. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0225-8 · Cited by 1,241
Immunogenic death of colon cancer cells treated with oxaliplatin
Tesniere, A., Schlemmer, F., Boige, V, Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apetoh, L., Barault, L., et al. (2010) · Oncogene · doi:10.1038/onc.2009.356 · Cited by 1,173
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042
Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine
Pauli, C., Hopkins, B. D., Prandi, D., Shaw, R., Fedrizzi, T., Sboner, A., Sailer, V., Augello, M., Puca, L., Rosati, R., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1154 · Cited by 937
Bracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.67 · Cited by 928
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
Tian, L., Goldstein, A., Wang, H., Ching Lo, H., Sun Kim, I., Welte, T., Sheng, K., Dobrolecki, L. E., Zhang, X., Putluri, N., et al. (2017) · Nature · doi:10.1038/nature21724 · Cited by 841
Chao, M. P., Jaiswal, S., Weissman-Tsukamoto, R., Alizadeh, A. A., Gentles, A. J., Volkmer, J., Weiskopf, K., Willingham, S. B., Raveh, T., Park, C. Y., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001375 · Cited by 776
HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses
Yanai, H., Ban, T., Wang, Z., Choi, M. K., Kawamura, T., Negishi, H., Nakasato, M., Lu, Y., Hangai, S., Koshiba, R., et al. (2009) · Nature · doi:10.1038/nature08512 · Cited by 688
Immune parameters affecting the efficacy of chemotherapeutic regimens
Zitvogel, L., Kepp, O., & Kroemer, G. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.223 · Cited by 669
Apetoh, L., Ghiringhelli, F., Tesniere, A., Criollo, A., Ortiz, C., Lidereau, R., Mariette, C., Chaput, N., Mira, J., Delaloge, S., et al. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00573.x · Cited by 574
Balachandran, V. P., Cavnar, M. J., Zeng, S., Bamboat, Z. M., Ocuin, L. M., Obaid, H., Sorenson, E. C., Popow, R., Ariyan, C., Rossi, F., et al. (2011) · Nature Medicine · doi:10.1038/nm.2438 · Cited by 521
The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy
Ahlmann, M., & Hempel, G. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3152-1 · Cited by 499
Soriani, A., Zingoni, A., Cerboni, C., Iannitto, M. L., Ricciardi, M. R., Di Gialleonardo, V., Cippitelli, M., Fionda, C., Petrucci, M. T., Guarini, A., et al. (2009) · Blood · doi:10.1182/blood-2008-08-173914 · Cited by 460
Machiels, J.-P., Reilly, R. T., Emens, L. A., Ercolini, A. M., Lei, R. Y., Weintraub, D., Okoye, F. I., & Jaffee, E. M. (2001) · PubMed · Cited by 453
Martins, I., Kepp, O., Schlemmer, F., Adjemian, S., Tailler, M., Shen, S., Michaud, M., Menger, L., Gdoura, A., Tajeddine, N., et al. (2011) · Oncogene · doi:10.1038/onc.2010.500 · Cited by 414
Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response
Fucikova, J., Kralikova, P., Fialova, A., Brtnicky, T., Rob, L., Bartunkova, J., & Špíšek, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0950 · Cited by 392
Spisek, R., Charalambous, A., Mazumder, A., Vesole, D. H., Jagannath, S., & Dhodapkar, M. V. (2007) · Blood · doi:10.1182/blood-2006-10-054221 · Cited by 388
Combination of antiangiogenesis with chemotherapy for more effective cancer treatment
Ma, J., & Waxman, D. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0715 · Cited by 370
Self-citationSchiavoni, G., Sistigu, A., Valentini, M., Mattei, F., Sestili, P., Spadaro, F., Sanchez, M., Lorenzi, S., D'Urso, M. T., Belardelli, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2788 · Cited by 362
CD73: a potent suppressor of antitumor immune responses
Beavis, P. A., Stagg, J., Darcy, P. K., & Smyth, M. J. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.02.009 · Cited by 355
Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments
Inoue, H., & Tani, K. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.84 · Cited by 347
Laheru, D., Lutz, E., Burke, J., Biedrzycki, B., Solt, S., Onners, B., Tartakovsky, I., Nemunaitis, J., Le, D., Sugar, E., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0371 · Cited by 346
TLR agonists: our best frenemy in cancer immunotherapy
Kaczanowska, S., Joseph, A. M., & Davila, E. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1012501 · Cited by 339
Landscape of tumor-infiltrating T cell repertoire of human cancers
Li, B., Li, T., Pignon, J.-C., Wang, B., Wang, J., Shukla, S. A., Dou, R., Chen, Q., Hodi, F. S., Choueiri, T. K., et al. (2016) · Nature Genetics · doi:10.1038/ng.3581 · Cited by 306
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy
Pol, J., Vacchelli, E., Aranda, F., Castoldi, F., Eggermont, A., Cremer, I., Sautès-Fridman, C., Fucikova, J., Galon, J., Spisek, R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008866 · Cited by 305
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design
Sistigu, A., Viaud, S., Chaput, N., Bracci, L., Proietti, E., & Zitvogel, L. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0245-0 · Cited by 305
Borg, C., Terme, M., Taïeb, J., Ménard, C., Flament, C., Robert, C., Maruyama, K., Wakasugi, H., Angevin, E., Thielemans, K., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21102 · Cited by 302
Current status and perspectives of patient-derived xenograft models in cancer research
Lai, Y., Wei, X., Lin, S., Qin, L., Cheng, L., & Li, P. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0470-7 · Cited by 295
Trial watch: Chemotherapy with immunogenic cell death inducers
Vacchelli, E., Senovilla, L., Eggermont, A., Fridman, W. H., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.23510 · Cited by 265
Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model
Banissi, C., Ghiringhelli, F., Chen, L., & Carpentier, A. F. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-009-0671-1 · Cited by 255
Kareva, I., Waxman, D. J., & Lakka Klement, G. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.12.039 · Cited by 249
Self-citationChemoimmunotherapy: Reengineering Tumor Immunity
Chen, G., & Emens, L. A. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1388-0 · Cited by 242
Emens, L. A., Asquith, J. M., Leatherman, J. M., Kobrin, B. J., Petrik, S., Laiko, M., Levi, J., Daphtary, M. M., Biedrzycki, B., Wolff, A. C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3494 · Cited by 236
Garg, A. D., De Ruysscher, D., & Agostinis, P. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1069938 · Cited by 230
Antibody‐dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells
Ochoa, M. C., Minute, L., Rodriguez, I., Garasa, S., Perez‐Ruiz, E., Inogés, S., Melero, I., & Berraondo, P. (2017) · Immunology & Cell Biology · doi:10.1038/icb.2017.6 · Cited by 230
Greten, T. F., Forner, A., Korangy, F., N'Kontchou, G., Barget, N., Ayuso, C., Ormandy, L. A., Manns, M. P., Beaugrand, M., & Bruix, J. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-209 · Cited by 208
Therapeutic targeting of myeloid-derived suppressor cells
Ugel, S., Delpozzo, F., Desantis, G., Papalini, F., Simonato, F., Sonda, N., Zilio, S., & Bronte, V. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.06.014 · Cited by 206
CpG Still Rocks! Update on an Accidental Drug
Krieg, A. M. (2012) · Nucleic Acid Therapeutics · doi:10.1089/nat.2012.0340 · Cited by 187
Update on NCI in vitro drug screen utilities
Holbeck, S. L. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2003.11.022 · Cited by 173
Trial Watch: Chemotherapy with immunogenic cell death inducers
Vacchelli, E., Aranda, F., Eggermont, A. M. M., Galon, J., Sautès‐Fridman, C., Cremer, I., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.27878 · Cited by 173
Low-dose metronomic chemotherapy: A systematic literature analysis
Lien, K., Georgsdottir, S., Sivanathan, L., Chan, K., & Emmenegger, U. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.06.038 · Cited by 170
Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination
Melero, I., Grimaldi, A. M., Perez-Gracia, J. L., & Ascierto, P. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2214 · Cited by 170
HMGB1: The Central Cytokine for All Lymphoid Cells
Li, G., Liang, X., & Lotze, M. T. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00068 · Cited by 166
Tanaka, H., Matsushima, H., Mizumoto, N., & Takashima, A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1101 · Cited by 163
Cancer immunotherapies, their safety and toxicity
Alatrash, G., Jakher, H., Stafford, P., & Mittendorf, E. A. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.795944 · Cited by 152
Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model
Wada, S., Yoshimura, K., Hipkiss, E. L., Harris, T. J., Yen, H., Goldberg, M. V., Grosso, J. F., Getnet, D., Marzo, A. M. D., Netto, G. J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4102 · Cited by 152
Penel, N., Adenis, A., & Bocci, G. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.04.009 · Cited by 149
Butt, A., & Mills, K. H. G. (2013) · Oncogene · doi:10.1038/onc.2013.432 · Cited by 146
Feng, L., Sun, X., Csizmadia, E., Han, L., Shu, B., Murakami, T., Wang, X., Robson, S. C., & Wu, Y. (2011) · Neoplasia · doi:10.1593/neo.101332 · Cited by 145
Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set
Sukkurwala, A. Q., Adjemian, S., Senovilla, L., Michaud, M., Spaggiari, S., Vacchelli, E., Baracco, E. E., Galluzzi, L., Zitvogel, L., Kepp, O., et al. (2014) · OncoImmunology · doi:10.4161/onci.28473 · Cited by 144
CpG Oligonucleotides as Cancer Vaccine Adjuvants
Shirota, H., Tross, D., & Klinman, D. M. (2015) · Vaccines · doi:10.3390/vaccines3020390 · Cited by 143
Surface‐exposed calreticulin in the interaction between dying cells and phagocytes
Martins, I., Kepp, O., Galluzzi, L., Senovilla, L., Schlemmer, F., Adjemian, S., Menger, L., Michaud, M., Zitvogel, L., & Kroemer, G. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05740.x · Cited by 123
Ellebæk, E., Engell-Noerregaard, L., Iversen, T. Z., Frøsig, T. M., Ahmad, S. M., Hadrup, S. R., Andersen, M. H., & Svane, I. M. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1242-4 · Cited by 121
Tongu, M., Harashima, N., Monma, H., Inao, T., Yamada, T., Kawauchi, H., & Harada, M. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1343-0 · Cited by 118
Salem, M. L., Diaz-Montero, C. M., Al-Khami, A. A., El-Naggar, S. A., Naga, O. S., Montero, A. J., Khafagy, A., & Cole, D. J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801829 · Cited by 115
Radojčić, V., Bezak, K. B., Škarica, M., Pletneva, M., Yoshimura, K., Schulick, R. D., & Luznik, L. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0734-3 · Cited by 113
der Most, R. G. V., Currie, A. J., Cleaver, A. L., Salmons, J., Nowak, A. K., Mahendran, S., Larma, I., Prosser, A., Robinson, B. W. S., Smyth, M. J., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006982 · Cited by 109
Autophagy Induced by Conventional Chemotherapy Mediates Tumor Cell Sensitivity to Immunotherapy
Ramakrishnan, R., Huang, C., Cho, H.-I., Lloyd, M. C., Johnson, J., Ren, X., Altiok, S., Sullivan, D. M., Weber, J. S., Celis, E., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2236 · Cited by 109
Fine, J. H., Chen, P., Mesci, A., Allan, D., Gasser, S., Raulet, D. H., & Carlyle, J. R. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1316 · Cited by 105
Wu, J., & Waxman, D. J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1005521 · Cited by 102
Self-citationChemoImmunoModulation: Immune Regulation by the Antineoplastic Chemotherapeutic Agents
Shurin, M. R., Naiditch, H., Gutkin, D. W., Umansky, V., & Shurin, G. V. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712800099785 · Cited by 96
Doloff, J. C., & Waxman, D. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3380 · Cited by 95
Self-citationKono, K., Mimura, K., & Kiessling, R. W. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.207 · Cited by 91
Cook, A., McDonnell, A. M., Lake, R., & Nowak, A. K. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1066062 · Cited by 88
Computational Approaches to Toll-Like Receptor 4 Modulation
Billod, J., Lacetera, A., Guzman‐Caldentey, J., & Martín‐Santamaría, S. (2016) · Molecules · doi:10.3390/molecules21080994 · Cited by 88
Redeker, A., & Arens, R. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00345 · Cited by 88
Moschella, F., Torelli, G. F., Valentini, M., Urbani, F., Buccione, C., Petrucci, M. T., Natalino, F., Belardelli, F., Foà, R., & Proietti, E. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3666 · Cited by 87
Moschella, F., Valentini, M., Aricò, E., Macchia, I., Sestili, P., D’Urso, M. T., Alessandri, C., Belardelli, F., & Proietti, E. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4523 · Cited by 81
Xu, C., Zhang, Y., Rolfe, A., Hernández, V. M., Guzman, W., Kradjian, G., Marelli, B., Qin, G., Qi, J., Wang, H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0483 · Cited by 81
Kareva, I. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102134 · Cited by 80
Peng, S., Lyford-Pike, S., Akpeng, B., Wu, A. A., Hung, C., Hannaman, D., Saunders, J. R., Wu, T. ‐., & Pai, S. I. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1322-5 · Cited by 77
Du, B., & Waxman, D. J. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.11.025 · Cited by 77
Self-citationFilipazzi, P., Pilla, L., Mariani, L., Patuzzo, R., Castelli, C., Camisaschi, C., Maurichi, A., Cova, A., Rigamonti, G., Giardino, F., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1516 · Cited by 76
Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer
Loven, D., Hasnis, E., Bertolini, F., & Shaked, Y. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.07.015 · Cited by 75
Chen, C.-S., Doloff, J. C., & Waxman, D. J. (2014) · Neoplasia · doi:10.1593/neo.131910 · Cited by 70
Self-citationTherapeutic Applications of Nucleic Acids and Their Analogues in Toll-like Receptor Signaling
Gosu, V., Basith, S., Kwon, O., & Choi, S. (2012) · Molecules · doi:10.3390/molecules171113503 · Cited by 67
Metronomic Chemotherapy: Direct Targeting of Cancer Cells after all?
André, N., Tsai, K. K., Carré, M., & Pasquier, E. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.03.011 · Cited by 63
Wu, J., & Waxman, D. J. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.07.033 · Cited by 59
Self-citationKhallouf, H., Märten, A., Serba, S., Teichgräber, V., Büchler, M. W., Jäger, D., & Schmidt, J. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31824b3a76 · Cited by 58
Song, Z., Yu, X., & Zhang, Y. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.07.013 · Cited by 57
Parra, K., Valenzuela, P., Lerma, N., Gallegos, A., Reza, L. C., Rodriguez, G., Emmenegger, U., Desidero, T. D., Bocci, G., Felder, M. S., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2016.429 · Cited by 51
Chen, J., Huang, X., Huang, G., Chen, Y., Chen, L., & Song, H. (2012) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2011.1116 · Cited by 50
A Review of Mechanisms of Circumvention and Modulation of Chemotherapeutic Drug Resistance
O'Connor, R. A. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909788166583 · Cited by 49
Targeting neoantigens for cancer immunotherapy: Table 1.
Lu, Y., & Robbins, P. F. (2016) · International Immunology · doi:10.1093/intimm/dxw026 · Cited by 48
Wu, J., Jordan, M., & Waxman, D. J. (2016) · BMC Cancer · doi:10.1186/s12885-016-2597-2 · Cited by 44
Self-citationConnor, J. P., Cristea, M. C., Lewis, N. L., Lewis, L. D., Komarnitsky, P. B., Mattiacci, M. R., Felder, M. A. R., Stewart, S., Harter, J. M., Henslee-Downey, J. P., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-20 · Cited by 43
Ye, J., Mills, B. N., Zhao, T., Han, B. J., Murphy, J. D., Patel, A. P., Johnston, C. J., Lord, E. M., Belt, B. A., Linehan, D. C., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0373 · Cited by 43
Mechanism and Therapeutic Reversal of Immune Suppression in Cancer
Herber, D. L., Nagaraj, S., Djeu, J. Y., & Gabrilovich, D. I. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0897 · Cited by 40
The exploitation of Toll-like receptor 3 signaling in cancer therapy
Glavan, T., & Pavelic, J. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612820666140826153347 · Cited by 38
Jordan, M., & Waxman, D. J. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.11.029 · Cited by 37
Self-citationLi, J., & Waxman, D. J. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.11.055 · Cited by 28
Self-citationMalvicini, M., Alaniz, L. D., Bayo, J., García, M. G., Piccioni, F., Fiore, E. J., Atorrasagasti, C., Aquino, J. B., Matar, P., & Mazzolini, G. D. (2012) · OncoImmunology · doi:10.4161/onci.20684 · Cited by 28
Stathopoulos, A., Pretto, C. M., Devillers, L., Denis, P., Hofman, F. M., Kruse, C. A., Jadus, M. R., Chen, T. C., & Schijns, V. E. C. J. (2012) · OncoImmunology · doi:10.4161/onci.19068 · Cited by 28
Liseth, K., Ersvær, E., Hervig, T. A., & Bruserud, Ø. (2010) · BioMed Research International · doi:10.1155/2010/692097 · Cited by 28
Doloff, J. C., Chen, C.-S., & Waxman, D. J. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-158 · Cited by 26
Self-citationLeong, W. I., Ames, R. Y., Haverkamp, J. M., Torres, L., Kline, J., Bans, A., Rocha, L., Gallotta, M., Guiducci, C., Coffman, R. L., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.27322 · Cited by 23
Lasalvia-Prisco, E., Goldschmidt, P., Galmarini, F. C., Cucchi, S., Vázquez, J., Aghazarian, M., Lasalvia-Galante, E., Golomar, W., & Gordon, W. (2012) · Medical Oncology · doi:10.1007/s12032-012-0301-1 · Cited by 22
Pantziarka, P., Hutchinson, L., André, N., Benzekry, S., Bertolini, F., Bhattacharjee, A., Chiplunkar, S. V., Duda, D. G., Gota, V., Gupta, S., et al. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2016.689 · Cited by 17
Self-citationMondino, A., Vella, G., & Icardi, L. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.006 · Cited by 16
Tumor Immunology: Basic and Clinical Advances
Beatty, P. L., Cascio, S., & Lutz, E. R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0717 · Cited by 10
Cited by
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Galluzzi, L., Vitale, I., Warren, S., Adjemian, S., Agostinis, P., Martinez, A. B., Chan, T. A., Coukos, G., Demaria, S., Deutsch, E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000337 · Cited by 1,119
Breast cancer: Biology, biomarkers, and treatments
Barzaman, K., Karami, J., Zarei, Z., Hosseinzadeh, A., Kazemi, M. H., Moradi-Kalbolandi, S., Safari, E., & Farahmand, L. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106535 · Cited by 973
Paradigms on Immunotherapy Combinations with Chemotherapy
Salas-Benito, D., Pérez-Gracia, J. L., Ponz-Sarvisé, M., Rodriguez-Ruiz, M. E., Martínez-Forero, I., Castañón, E., López-Picazo, J. M., Sanmamed, M. F., & Melero, I. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1312 · Cited by 407
Tumor neoantigens: from basic research to clinical applications
Jiang, T., Shi, T., Zhang, H., Hu, J., Song, Y., Wei, J., Ren, S., & Zhou, C. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0787-5 · Cited by 386
Metal Drugs and the Anticancer Immune Response
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355
Metadata
- Authors
- Wu, J., & Waxman, D. J.
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2018-04
- Volume
- 419
- Pages
- 210-221
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W2790541566
- Cited by
- 320
- References
- 123
- FWCI
- 11.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.